INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...

INDIANAPOLIS, Sept. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee ...

While sales continue to lag, Lilly has made a hard pitch to payers for Emgality, and so far it appears to be working: Emgality prescriptions were three-quarters paid for as of last week, and 91.5% ...

Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered ...

Eli Lilly’s CGRP migraine prevention drug Emgality is in a heated market share race with Amgen’s Aimovig and Teva’s Ajovy, but in the second quarter, it gained some steam. By the end of the ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.

Teva sued Lilly in 2018, claiming Emgality infringes patents for its competing drug Ajovy. The patents cover methods of using antibodies that treat migraines by inhibiting peptides that cause them.

Lilly's Emgality was approved in 2018 in the U.S. for preventive treatment of migraine in adults, and Pfizer's Nurtec ODT in 2020 for treatment of acute migraine and its use was expanded to cover ...

Eli Lilly (NYSE:LLY) and Organon (NYSE:OGN) have expanded their commercialization deal for migraine medicine Emgality ...

Lilly said its direct-to-consumer service will also be available for patients with diabetes and migraine, with the website’s pharmacy page listing migraine drug Emgality, insulin and similar … ...